

Identification of Promising Lead Compounds from *Capsicum annuum* Targeting BACE-1 for Alzheimer's Disease Therapy: A Molecular Docking Study

Aisiri Vijayasimha¹, Samiksha Bhor^{2,*}

Abstract

Background: Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions of people worldwide. Beta-secretase 1 (BACE-1) is an important therapeutic target for AD treatment. *Capsicum annuum* (CA) is a commonly consumed plant with potential neuroprotective properties. In this study, we aimed to identify potential lead compounds from CA that can target BACE-1 for AD therapy using molecular docking. **Methods:** A library of 15 compounds from CA was obtained from PubChem, and their structures were optimized using PyRx-v0.8. BACE-1 protein structure was obtained from the Protein Data Bank (PDB). Docking simulations were performed using PyRx-v0.8, and the results were analyzed using BIOVIA Discovery Studio 2019. **Results:** Among the studied 15 ligands, the best binding affinity was shown by six compounds. Capsaicin, dihydrocapsaicin, apigenin, riboflavin, quercetin, and luteolin had a binding affinity of -6.4, -8.4, -8.4, -8.5, and -8.7 kcal/mol, respectively. Luteolin had the highest binding score of -8.7 kcal/mol, this indicates its best possible inhibitory action with BACE-1. **Conclusion:** Our study identified dihydrocapsaicin and capsaicin from CA as promising lead compounds that can target BACE-1 for AD therapy. Further in vitro and in vivo studies are needed to validate their therapeutic potential.

Keywords: Alzheimer's disease, *Capsicum annuum*, BACE-1, molecular docking

INTRODUCTION

Alzheimer's disease (AD) is a neurological disorder characterized by progressive memory and cognitive loss, including impaired judgment and decision-making, and is typically accompanied by various neuropsychiatric symptoms such as depression, apathy, anxiety, agitation, delusions, and hallucinations [1]. The causes of AD have not been fully understood, although it has been estimated that a combination of factors such as age-related changes in the brain, along with genetic, environmental, and lifestyle factors might influence the onset of AD. From 1990 to 2019, the AD burden

increased worldwide, with an overwhelming population of 50 million people living with AD in 2021 [2]. To date, only symptomatic treatment is available, which counterbalances the neurotransmitter disturbance of the disease [3]. Current treatments include symptomatic approaches such as the usage of acetylcholinesterase inhibitors and N-methyl d-aspartate (NMDA) [4]. Anticholinesterase work by preventing the action of the enzyme anticholinesterase, thereby reducing the symptoms levels of AD. NMDA antagonists' function by reducing the increasing levels of NMDA receptor hypofunction. These treatments cannot completely cure AD, but they help stabilize the symptoms for a limited period of time.

*Author for Correspondence

Samiksha Bhor

E-mail: SamikshaB@bionome.in

¹Student, Department of Bioinformatics, BioNome Private Limited, Bengaluru, Karnataka, India

²Bioinformatics Associate, Department of Bioinformatics, BioNome Private Limited, Bengaluru, Karnataka, India

Received Date: April 13, 2023

Accepted Date: May 06, 2023

Published Date: May 18, 2023

Citation: Aisiri Vijayasimha, Samiksha Bhor. Identification of Promising Lead Compounds from *Capsicum annuum* Targeting BACE-1 for Alzheimer's Disease Therapy: A Molecular Docking Study. International Journal of Genetic Modifications and Recombinations. 2023;1(1): 43–52p.

Several studies have reported and supported the amyloid-beta (A β) pathway in the slow progression of AD which involves the cleavage of amyloid precursor protein (APP) into amyloid-beta peptides (A β) by β -secretase (β -APP-cleaving enzyme-1 (BACE1)) and γ -secretase enzymes [5]. In patients with Alzheimer's disease, dense A β aggregates develop between neurons in several regions of the brain and as a result, cell-to-cell signaling is disrupted. While symptomatic therapies work to improve cognitive functions and reduce AD symptoms there is an imminent need to develop disease-modifying therapies that can target the amyloid-beta pathway and effectively prevent or diminish A β aggregates in brain regions.

Common pathological features of AD include oxidative stress, accumulation of certain aggregated proteins, and neuroinflammation [6]. Fighting chronic disease with phytochemicals or herbal medicine has become a hot topic recently, and numerous studies using phytochemicals for treating neurological disorders have been published. Phytochemicals with antioxidant properties could be beneficial in treatment since they can reduce oxidative stress and inflammation. *Justicia adhatoda* L., *Ferula assafoetida* L., *Amorphophallus paeoniifolius*, *Catharanthus roseus*, *Ginkgo biloba* L., *Panax ginseng*, and *Zingiber officinale* are some plants whose extracts possess anti-inflammatory properties and could be useful in treating AD and other neurological disorders [7]. *Capsicum annuum* is one such plant, with high levels of water and carbohydrates [8]. Bell peppers supply considerable phytochemicals with high antioxidant capacities, such as phenols, flavonoids, and carotenoids. Colored bell peppers are a good source of antioxidant compounds important for dietary consideration because they can prevent the formation of free radicals that can harm human cells. Extracts (fruits and leaves) can also modulate the immune response, exerting anti-inflammatory properties and promoting the production of antibodies [9]. More research is necessary to help evaluate the role of phytochemical compounds in the treatment of AD and other neurological disorders.

Thus, in this study, we aim to identify phytochemical compounds from *Capsicum annuum* plant extracts as potential drug compounds by docking the ligand molecules with BACE-1 protein.

MATERIALS AND METHODS

Retrieval of Ligands

Based on our literature review, phytochemicals with antioxidant and anti-inflammatory properties could exert neuroprotective effects in various brain pathologies. From our literature review, we identified fifteen such phytocompounds from the *Capsicum annuum* plant, with the help of the IMPPAT database (Indian Medicinal Plants, Phytochemistry and Therapeutics) [10]. The selected phytochemicals are secondary metabolites such as flavonoids, polyphenols, terpenoids, and alkaloids. The library of ligands includes, 3-methyl-2-butanone (PubChem ID:11251), luteolin (PDB ID: 5280445), 2-methyl-3-pentanone (PubChem ID: 11265), hexadecane (PubChem ID: 11006), pentyl butyrate (PubChem ID: 10890), octanal (PubChem ID: 454), riboflavin (PubChem ID: 493570), isobutyl 2-methyl butyrate (PubChem ID: 102820), geranylacetone (PubChem ID: 19633), capsaicin (PubChem ID: 1548943), dihydrocapsaicin (PDB ID: 107982), 2-acetylpyrrole (PubChem ID: 14079), and 2-tridecanone (PubChem ID: 11622). Quercetin (PubChem ID: 5280343), and apigenin (PubChem ID: 5280443). The ligands' PDB structures were obtained in SDF format from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>). The ligands were then subjected to energy minimization using a Universal Force Field (UFF) and converted to Autodock-compatible PDBQT format using PyRx-v0.8.

Retrieval and Preparation of Protein Target

After conducting an extensive systematic review of the literature, the protein BACE-1 (PDB ID: 1M4H) was identified as the protein target. BACE-1 is a class of hydrolase proteins that breaks down the APP at the β -site [11]. This makes BACE-1 an important factor in the production and release of A β peptide in the brain. The three-dimensional (3D) structure of the protein was retrieved from the RCSB Protein Data Bank in PDB format. The selection of the PDB structure was made according to previous reports [12]. 1M4H has shown a reasonable resolution of 2.10Å and the structure was determined using

the X-ray diffraction method. The protein cleaning and preparation processes were performed using BIOVIA Discovery Studio Visualizer-v21.1.0.20298, which involved the removal of water molecules, native ligands, and hetero atoms, and the addition of polar hydrogen. The purified protein was then imported into PyRx-v0.8 software, where it was transformed into Autodock-compatible PDBQT format and optimized for docking purposes.

Molecular Docking and Visualization

Molecular Docking is a computational approach to finding potential drug targets by modeling protein-ligand interactions. PyRx-v0.8 was used to carry out the docking analysis. All fifteen ligands were individually docked with the target in separate docking runs. A blind docking approach was employed to predict the binding affinity energies. The grid box dimensions for the target protein were set as $115.73 \times 76.89 \times 101.67 \text{ \AA}$ having center dimensions of $-3.57 \times 40.74 \times 11.31 \text{ \AA}$. Results were recorded according to the Root Mean Square Deviation (RMSD) criterion and in this study, we have selected ligands with 0 RMSD values. All other docking parameters were set to default. Protein-ligand interactions having the best binding affinity scores were selected for visualization in BIOVIA Discovery Studio. The interactions were analyzed in a 2D diagram.

RESULTS AND DISCUSSION

Structural Assessment of BACE-1

BACE-1, also known as beta-secretase, is a type-I transmembrane aspartic protease enzyme that cleaves APP to generate beta-amyloid peptide, which is a major component of the amyloid plaques found in the brains of AD patients. The crystal structure of BACE-1 has been determined by X-ray crystallography, with PDB ID 1M4H. The BACE-1 protein structure is comprised of two domains: an N-terminal domain and a catalytic domain. Ramachandran plots and values of the purified protein structure indicated that 87.8% of residues were in favored regions and 11.5% of residues were present in allowed regions.

ADME Analysis

The ADME properties—absorption, distribution, metabolism, and excretion for potential drug molecules can be predicted with the help of several in silico models. In our study, we used SwissADME (<http://www.swissadme.ch/>) for performing ADME analysis for the fifteen phytochemical compounds.

The predicted properties such as molecular weight (g/mol), molar volume (cm^3/mol), and molar refractivity were evaluated to justify their drug-likeness behavior. All compounds justified the standard values according to Lipinski's rule of five. The results are presented in Table 1. The molecular mass of all fifteen phytochemical compounds was found in the range of 80 to 380. All compounds had < 5 hydrogen bond donors, except riboflavin, which had five hydrogen bond donors. All 15 compounds had < 10 hydrogen bond acceptors. The molecular refractivity of all compounds was observed to be between 20 to 100. The MlogP value was in the range of +0.05 to +3.7. Only one compound, hexadecane had a high value of +6.42, whereas the rest of the compounds had a MlogP value < 5 .

Pharmacokinetics properties were assessed to confirm the efficacy of candidate molecules. In ADME evaluation, solubility ($\log \text{ mol/L}$), bioavailability, and absorption (% absorbed) predicted values justified the strong therapeutic potential of the phytocompounds. MlogP values were considered for accurate prediction of lipophilicity. Ideally, a MlogP value < 5 is considered good for better compound absorptions, permeation, and distribution. Water solubility was predicted using the Silicos IT LogSw descriptor of SwissADME, which follows the fragmental method as opposed to the topological methods followed by ESOL and Ali methods. In the SwissADME LogSw scale, compounds with values less than -6 are considered to be poorly soluble. In our study, the log S value was predicted in the range of 0 to -4.7, indicating that most compounds are moderately soluble in water. Only Hexadecane had a log S value of -6.33, describing poor solubility in water. The pharmacokinetics study results are presented in Table 2.

Table 1. Drug-likeness analysis.

Phytocompounds	Molecular weight	H-bond donors	H-bond acceptors	Molecular refractivity	MlogP
Apigenin	270.24	3	5	73.99	0.52
3-methyl-2-butanone	86.13	0	1	26.35	1.01
Quercetin	568.87	2	2	186.76	-0.56
2-methyl-3-pentanone	100.16	0	1	31.16	1.39
Hexadecane	226.44	0	0	79.03	6.44
Pentyl butyrate	158.24	0	2	46.66	2.28
Dihydrocapsaicin	307.43	2	3	90.99	2.78
Octanal	128.21	0	1	40.77	2.07
Riboflavin	376.36	5	8	96.99	-0.54
Isobutyl 2-methylbutyrate	158.24	0	2	46.66	2.28
Geranylacetone	194.31	0	1	63.86	3.34
Capsaicin	305.41	2	3	90.52	2.69
Luteolin	318.24	6	8	80.06	-1.08
2-acetylpyrrole	109.13	1	1	30.99	-0.18
2-tridecanone	198.34	0	1	64.80	3.54

Table 2. Pharmacokinetics assessment.

Phytocompounds	logS	Gastrointestinal absorption	Blood-Brain barrier permeant	P-gp substrate	Bioavailability
Apigenin	-3.94	High	No	No	0.55
3-methyl-2-butanone	-0.93	High	Yes	No	0.55
Quercetin	-3.16	High	No	No	0.55
2-methyl-3-pentanone	-1.36	High	Yes	No	0.55
Hexadecane	-6.33	Low	No	No	0.55
Pentyl butyrate	-2.76	High	Yes	No	0.55
Dihydrocapsaicin	-5.59	High	Yes	No	0.55
Octanal	-2.6	High	Yes	No	0.55
Riboflavin	-2.62	Low	No	No	0.55
Isobutyl 2-methylbutyrate	-2.01	High	Yes	No	0.55
Geranylacetone	-3.18	High	Yes	No	0.55
Capsaicin	-4.87	High	Yes	No	0.55
Luteolin	-0.97	Low	No	No	0.55
2-Acetylpyrrole	-1.88	High	Yes	No	0.55
2-Tridecanone	-4.66	High	Yes	No	0.55

The predictions of human gastrointestinal absorption (HIA) were done using the BOILED-Egg Model of SwissADME. The model returns “high” or “low” if the molecule under investigation has a high or low rate of absorption in the gastrointestinal tract. All compounds, except for hexadecane and riboflavin showed “high”. The model returns “yes” or “no” if the molecule has a higher or lower probability of being a substrate of P-gp. From the SwissADME model, we identified that apigenin, quercetin, luteolin, and riboflavin were not blood–brain barrier (BBB) permeant which could be a hindrance in their potential drug characteristics. It was also observed that none of the compounds forms a substrate with P-gp, which is another favorable factor for the compounds to behave as potential drug candidates. Based on this analysis, all the compounds passed the acceptable criteria for potential drug properties and were considered for docking with the target protein.


Molecular Docking




All fifteen compounds were docked with BACE-1 crystallized protein structure. The docked complexes were analyzed based on the lowest binding energy (kcal/mol). The best pose selection from all the docking complexes was also conducted based on the lowest binding energy values. The binding energy values were in the range of -4.2 to -8.7 kcal/mol, which is considered good. Only the ligands that had relatively lower binding energy scores were considered best among the fifteen compounds. The docking results are represented in Table 3.

Table 3. Molecular docking with BACE-1.

Phytocompounds	Binding affinity (kcal/mol)
Apigenin	-8.4
3-methyl-2-butanone	-4.2
Quercetin	-8.5
2-methyl-3-pentanone	-4.1
Hexadecane	-4.6
Pentyl butyrate	-4.6
Dihydrocapsaicin	-7.1
Octanal	-4.6
Riboflavin	-8.4
Isobutyl 2-methylbutyrate	-4.7
Geranylacetone	-6
Capsaicin	-6.4
Luteolin	-8.7
2-acetylpyrrole	-4.8
2-tridecanone	-4.9

Among the fifteen ligands, the best binding affinity was shown by six compounds. Capsaicin, dihydrocapsaicin, apigenin, riboflavin, quercetin, and luteolin had a binding affinity of -6.4, -8.4, -8.4, -8.5, and -8.7 kcal/mol respectively. Luteolin had the highest binding score of -8.7 kcal/mol, this indicates its best possible inhibitory action with BACE-1. These compounds were visualized using BIOVIA Discovery Studio and the 2D interaction diagrams were studied. The interactions can be visualized in Figure 1.








Figure 1. Protein-ligand interaction visualization in BIOVIA Discovery Studio.

The ligand Quercetin displayed three H-bonding with BACE-1 at Tyr320, Thr75, Tyr60, and one π -alkyl bonding at Arg61. Dihydrocapsaicin showed one π - π T-shaped bonding at Trp277 and three H-bonding (Tyr60, Tyr320, Thr275). Apigenin showed two π -alkyl bonds (Val361 and Arg61) and two H-bonding (Trp277 and Asp318). Riboflavin showed one π -sigma bonding at Pro308, two π -alkyl bonding at Lys9 and Ala159, and three H-bonding at Ser10, Arg307 and Gly11. Capsaicin displayed one alkyl bonding at Tyr60, one π -alkyl bonding at Arg61, six carbon-hydrogen bonding at Asp363, Gln303, Trp277, Gly158, His362, and Thr 275, and two H-bonding. Luteolin showed one unfavorable donor-donor bonding at Arg61, one π -alkyl bonding at Val361, and three H-bonding at Asp62, Asp318, and Trp297.

DISCUSSION

Alzheimer's disease is a neurodegenerative disorder that affects the brain, causing a gradual decline in cognitive abilities, memory loss, and changes in behavior. One protein that plays an important role in the development of AD is beta-secretase 1 (BACE-1). BACE-1 cleaves the APP to form beta-amyloid

peptides. Beta-amyloid peptides are the main component of amyloid plaques that accumulate in the brains of AD patients. These plaques are toxic to neurons, leading to their death and the subsequent cognitive decline that characterizes the disease [13].

Studies have shown that BACE-1 levels are increased in the brains of AD patients and that reducing BACE-1 activity can prevent the formation of beta-amyloid plaques. Therefore, BACE-1 has become an attractive target for the development of AD treatments. Several drugs targeting BACE-1 have been developed, but so far, clinical trials have been disappointing. One reason for this may be that BACE-1 has other important functions in the brain, such as regulating synaptic plasticity, that are disrupted by blocking its activity [14]. Despite these challenges, the role of BACE-1 in the pathogenesis of AD is clear. Further research is needed to fully understand the complex functions of BACE-1 in the brain and to develop effective therapies that can target this enzyme without causing unwanted side effects.

The present study aimed to identify potential lead compounds from *Capsicum annuum* that can target BACE-1 for AD therapy. In silico molecular docking was performed to evaluate the binding affinity of fifteen phytochemical compounds with BACE-1, and the ADME properties of these compounds were also analyzed. The crystal structure of BACE-1 used in this study (PDB ID 1M4H) had high-quality refinement and was validated by Ramachandran plots. The results of ADME analysis showed that all fifteen phytochemical compounds were drug-like and had desirable pharmacokinetic properties, including good water solubility and bioavailability. These results suggest that these compounds could be potential candidates for AD therapy.

The molecular docking results revealed that six phytochemical compounds (capsaicin, dihydrocapsaicin, apigenin, riboflavin, quercetin, and luteolin) had the best binding affinity with BACE-1, with luteolin showing the highest binding score. This indicates that luteolin has the best inhibitory action with BACE-1, and could potentially be used as a lead compound for developing AD therapy. The interaction diagrams of the six compounds showed that they interacted with the active site of BACE-1 through hydrogen bonding and pi-alkyl bonding. The compounds quercetin and dihydrocapsaicin formed three and four hydrogen bonds with BACE-1, respectively, indicating their strong binding affinity with the protein.

Our study explores the potential of *Capsicum annuum*, a commonly used spice, as a source of lead compounds for AD therapy. The study provides important insights into the molecular mechanism of BACE-1 inhibition by these compounds, which can help in the design and development of more potent inhibitors. The use of molecular docking for the evaluation of the binding affinity of these compounds with BACE-1 is also an important contribution, as it provides a cost-effective and efficient way of screening potential drug candidates. From the ADME analysis, a better understanding of the compounds' pharmacokinetic and pharmacodynamic characteristics can be provided. This information can be used to design drugs that have improved bioavailability and efficacy. From the ADME analysis, it was discovered that ligands with the ability to permeate the BBB are more suitable as drug components [15]. However, in our study, we identified that out of the selected fifteen compounds, ten compounds were BBB permeant. Capsaicin and dihydrocapsaicin show high binding energy of -6.4 kcal/mol and -7.1 kcal/mol respectively and are both BBB permeants, making them the best-suited molecules to be considered for drug discovery. The study also highlights the importance of in silico methods in drug discovery and the potential of phytochemical compounds as drug candidates. The study's findings can pave the way for the development of more potent and effective BACE-1 inhibitors for AD therapy.

Overall, the present study provides valuable insights into the potential lead compounds from *Capsicum annuum* for developing AD therapy. The study's findings can pave the way for the development of more potent and effective BACE-1 inhibitors for AD therapy. These compounds showed good drug-like properties and strong binding affinity with BACE-1, making them promising candidates for further experimental validation. Further studies are needed to explore the efficacy and safety of these compounds in vivo and clinical trials.

CONCLUSION

Alzheimer's disease is a complex and multifactorial neurodegenerative disorder, for which there is no definitive cure yet. Current therapeutic options only provide symptomatic relief and do not address the underlying pathology of the disease. Therefore, the search for new treatments and preventive strategies for AD is a major area of research. Phytocompounds derived from plants have emerged as a promising alternative due to their multifaceted neuroprotective properties and low toxicity profiles [16]. The results of the present study highlight the potential of phytocompounds from *Capsicum annuum* as a source of lead compounds for the development of novel drugs for AD therapy. The six compounds (capsaicin, dihydrocapsaicin, apigenin, riboflavin, quercetin, and luteolin) identified in this study have shown promising inhibitory action on BACE-1, a key enzyme involved in the production of beta-amyloid plaques, a hallmark of AD. These compounds are also reported to behave as anti-oxidants and anti-inflammatory agents, which have potential neuroprotective properties [17–19]. Molecular docking studies have shown strong binding affinities of these compounds with BACE-1, suggesting their potential as inhibitors of beta-amyloid production.

Furthermore, the ADME analysis of these compounds has predicted their drug-like properties, indicating their suitability for further development as therapeutic agents. These phytocompounds have also shown good pharmacokinetic properties, with high gastrointestinal absorption rates, water solubility, and bioavailability.

In conclusion, phytocompounds derived from *Capsicum annuum* show great potential as novel therapeutic agents for AD, and further studies are warranted to validate their efficacy and safety. The future research direction in this field can focus on optimizing the identified lead compounds through structure-activity relationship (SAR) studies, in vivo pharmacological evaluations, and clinical trials to determine their efficacy in treating and preventing AD. The use of phytocompounds in combination with other therapies and drug delivery systems could also be explored to improve their bioavailability and efficacy.

REFERENCES

1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health*. 2022;7(2):e105–25. doi: 10.1016/S2468–2667(21)00249–8.
2. Sharma S. Alzheimer's disease: causes, treatment & basic science review. *IJCAAP*. 2021;6(3):108–16. doi: 10.18231/j.ijcaap.2021.020.
3. Atri A. Current and future treatments in Alzheimer's disease. *Semin Neurol*. 2019;39(2):227–40. doi: 10.1055/s-0039–1678581.
4. Geerts H, Grossberg GT. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. *J Clin Pharmacol*. 2006;46(7);Suppl 1:8S–16S. doi: 10.1177/0091270006288734.
5. Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N, et al. The β -secretase BACE1 in Alzheimer's disease. *Biol Psychiatry*. 2021;89(8):745–56. doi: 10.1016/j.biopsych.2020.02.001.
6. Chen XQ, Mobley WC. Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: converging insights from alternative hypotheses. *Front Neurosci*. 2019 May 7;13:446. doi: 10.3389/fnins.2019.00446.
7. Akram M, Nawaz A. Effects of medicinal plants on Alzheimer's disease and memory deficits. *Neural Regen Res*. 2017;12(4):660–70. doi: 10.4103/1673–5374.205108.
8. Thuphairo K, Sornchan P, Suttisansanee U. Bioactive compounds, antioxidant activity and inhibition of key enzymes relevant to Alzheimer's disease from sweet pepper (*Capsicum annuum*) extracts. *Prev Nutr Food Sci*. 2019;24(3):327–37. doi: 10.3746/pnf.2019.24.3.327.
9. Bakrim S, Aboulaghra S, El Menyiy N, El Omari N, Assaggaf H, Lee LH, et al. Phytochemical compounds and nanoparticles as phytochemical delivery systems for Alzheimer's disease management. *Molecules*. 2022;27(24):9043. doi: 10.3390/molecules27249043.

10. Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, Chand RPB, Aparna SR, Mangalapandi P et al. IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry and Therapeutics. *Sci Rep*. 2018;8(1):4329. doi: 10.1038/s41598-018-22631-z.
11. Vassar R, Kandalepas PC. The β -secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. *Alzheimers Res Ther*. 2011;3(3):20. doi: 10.1186/alzrt82.
12. Jabir NR, Rehman MT, Alsolami K, Shakil S, Zughaibi TA, Alserihi RF, et al. Concatenation of molecular docking and molecular simulation of BACE-1, γ -secretase targeted ligands: in pursuit of Alzheimer's treatment. *Ann Med*. 2021;53(1):2332-44. doi: 10.1080/07853890.2021.2009124.
13. Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. *J Neuropathol Exp Neurol*. 2007;66(12):1136-46. doi: 10.1097/nen.0b013e31815c5efb.
14. Rodriguez RD, Molina M, Leite RP, Sabadin R, Takada LT, Suemoto CK, et al. P1-359: Neuropathological findings of an early-onset dementia case with atypical Alzheimer's disease: how challenging can the clinical diagnosis of mixed ad be? *Alzheimers Dement*. 2018;14(7S_Part_8):1-359. doi: 10.1016/j.jalz.2018.06.367.
15. Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. *Fluids Barriers CNS*. 2020;17(1):69. doi: 10.1186/s12987-020-00230-3.
16. Piccialli I, Tedeschi V, Caputo L, D'Errico S, Ciccone R, De Feo V, et al. Exploring the therapeutic potential of phytochemicals in Alzheimer's disease: focus on polyphenols and monoterpenes. *Front Pharmacol*. 2022;13:876614. doi: 10.3389/fphar.2022.876614.
17. Marashly ET, Bohlega SA. Riboflavin has neuroprotective potential: focus on Parkinson's disease and migraine. *Front Neurol*. 2017;8:333. doi: 10.3389/fneur.2017.00333.
18. Janyou A, Wicha P, Jittiwat J, Suksamrarn A, Tocharus C, Tocharus J. Dihydrocapsaicin attenuates blood brain barrier and cerebral damage in focal cerebral ischemia/reperfusion via oxidative stress and inflammatory. *Sci Rep*. 2017 Sep 5;7(1):10556. doi: 10.1038/s41598-017-11181-5.
19. Pegorini S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, et al. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. *Br J Pharmacol*. 2005;144(5):727-35. doi: 10.1038/sj.bjp.0706115.